DiaMedica Therapeutics Inc.
NasdaqCM DMAC
DiaMedica Therapeutics Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -24.11 M
-
DiaMedica Therapeutics Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -19.43 M, a -46.35% change year over year.
-
DiaMedica Therapeutics Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -13.27 M, a 9.50% change year over year.
-
DiaMedica Therapeutics Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -14.67 M, a -34.05% change year over year.
-
DiaMedica Therapeutics Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -10.94 M.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
| CEO | Mr. Dietrich John Pauls MBA |
| IPO Date | Aug. 3, 2012 |
| Location | United States |
| Headquarters | Two Carlson Parkway |
| Employees | 18 |
| Sector | Health Care |
| Industries | |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Past 5 years
USD 14.84
USD 1.86
USD 4.57
USD 2.66
USD 11.16
USD 5.89
USD 1.96
USD 3.38
StockViz Staff
January 15, 2025
Any question? Send us an email